ArticleClinical autonomic research : official journal of the Clinical Autonomic Research Society2007
Treatment of autonomic neuropathy, postural tachycardia and orthostatic syncope with octreotide LAR.
Article in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Fix or Adapt? Rethinking the Management of Complex Autonomic Dysfunction in an Older Adult Following Orthopedic Surgery.Geriatrics & gerontology international · 2025Article
- Review
- Worsening Postural Tachycardia Syndrome Is Associated With Increased Glucose-Dependent Insulinotropic Polypeptide Secretion.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Do meals affect heart rate and symptoms in postural orthostatic tachycardia syndrome?Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2022Article
- The quest for biomarkers in postural tachycardia syndrome and other updates on recent autonomic research.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2020Article
- Water Ingestion in Postural Orthostatic Tachycardia Syndrome: A Feasible Treatment Option?The Journal of innovations in cardiac rhythm management · 2019Article
- Cardiovascular autonomic neuropathy.Proceedings (Baylor University. Medical Center) · 2016Article
- Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump.Case reports in medicine · 2015Article
- Cardiac autonomic neuropathy in patients with diabetes mellitus.World journal of diabetes · 2014 · on this mapReview
- Review
- Diagnosis and management of postural orthostatic tachycardia syndrome: A brief review.Journal of geriatric cardiology : JGC · 2012Article
- Postural tachycardia syndrome--current experience and concepts.Nature reviews. Neurology · 2011Review
- The location of the human volume indifferent point predicts orthostatic tolerance.European journal of applied physiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to determine whether autonomic neuropathy and the postural tachycardia syndrome can be treated with octreotide LAR (Long Acting Release). This was an open-label pilot project. Protocol 1 Patients with autonomic neuropathy (n = 4) were given increasing doses of octreotide LAR once a month for three months. Blood pressure was measured in the sitting posture every two weeks. Pretreatment mean blood pressure averaged 83.8 +/- 7.1 mm Hg. After four, six and eight weeks of therapy the blood pressures averaged 96.3 +/- 6.4, 98.2 +/- 6.1 (p < .025), and 104.1 +/- 3.1 (p < .025) respectively. Therapy led to a dramatic improvement in symptoms in one patient but another had an unacceptable elevation in supine blood pressure. Protocol 2 Patients with POTS or orthostatic intolerance were given 10, 20, or 30 mg of octreotide LAR over three months. Seven patients entered and five completed the study. After two months treatment, standing time increased from 36.0 +/- 9.2 to 59.2 +/- .8 minutes (p < .01). Heart rate in the standing position was suppressed from 106 +/- .83 to 93.2 +/- .8 beats per minute (p < .05). Orthostatic dizziness and chronic fatigue improved. We conclude that octreotide LAR can be used to treat autonomic neuropathy but there is a risk of an excessive pressor response. Octreotide LAR improved standing time and suppressed tachycardia in patients with orthostatic intolerance.
Indexed as
Identifiers
17767379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.